QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.061770v1 308/3/1040    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lau, Y. Y. Articles by Benet, L. Z. Search for Related Content PubMed PubMed Citation Articles by Lau, Y. Y. Articles by Benet, L. Z.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay

Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, California

The disposition of digoxin and the influence of the organic anion transporting polypeptide (Oatp)2 inhibitor rifampicin and the P-glycoprotein (P-gp) inhibitor quinidine on its hepatic disposition were examined in the isolated perfused rat liver. Livers from groups of rats were perfused in a recirculatory manner after a bolus dose of digoxin (10 µg), a dual substrate for Oatp2 and P-gp as well as CYP3A. Perfusions of digoxin were also examined in groups of rats in the presence of the inhibitors: rifampicin (100 µM) or quinidine (10 µM). In all experiments, perfusate samples were collected for 60 min. Digoxin and its primary metabolite were determined in perfusate and liver by liquid chromatography/mass spectrometry. The area under the curve (AUC) from 0 to 60 min was determined. The AUC ± S.D. of digoxin was increased from control (3880 ± 210 nM·min) by rifampicin (5200 ± 240 nM·min; p < 0.01) and decreased by quinidine (3220 ± 340 nM·min; P < 0.05). It is concluded that rifampicin limits the hepatic entrance of digoxin and reduced the hepatic exposure of digoxin to CYP3A by inhibiting the basolateral Oatp2 uptake transport, whereas quinidine increased the hepatic exposure of digoxin to CYP3A by inhibiting the canalicular P-gp transport. These data emphasize the importance of uptake and efflux transporters on hepatic drug metabolism.

Address correspondence to: Dr. Leslie Z. Benet, Department of Biopharmaceutical Sciences, 533 Parnassus, Room U-68, University of California, San Francisco, San Francisco, CA 9414-0446. E-mail: benet{at}itsa.ucsf.edu

This article has been cited by other articles:

				T. N. Lam and C. A. Hunt Discovering Plausible Mechanistic Details of Hepatic Drug Interactions Drug Metab. Dispos., January 1, 2009; 37(1): 237 - 246. [Abstract] [Full Text] [PDF]

				M. Sousa, A. Pozniak, and M. Boffito Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs J. Antimicrob. Chemother., November 1, 2008; 62(5): 872 - 878. [Abstract] [Full Text] [PDF]

				J. L. Lam, S. B. Shugarts, H. Okochi, and L. Z. Benet Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 864 - 870. [Abstract] [Full Text] [PDF]

				J. L. Lam, H. Okochi, Y. Huang, and L. Z. Benet IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY Drug Metab. Dispos., August 1, 2006; 34(8): 1336 - 1344. [Abstract] [Full Text] [PDF]

				Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM Drug Metab. Dispos., July 1, 2006; 34(7): 1175 - 1181. [Abstract] [Full Text] [PDF]

				Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 762 - 771. [Abstract] [Full Text] [PDF]

				L. Liu, E. Mak, R. G. Tirona, E. Tan, P. M. Novikoff, P. Wang, A. W. Wolkoff, and K. S. Pang Vascular Binding, Blood Flow, Transporter, and Enzyme Interactions on the Processing of Digoxin in Rat Liver J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 433 - 448. [Abstract] [Full Text] [PDF]

				G. Hartmann, V. Vassileva, and M. Piquette-Miller IMPACT OF ENDOTOXIN-INDUCED CHANGES IN P-GLYCOPROTEIN EXPRESSION ON DISPOSITION OF DOXORUBICIN IN MICE Drug Metab. Dispos., June 1, 2005; 33(6): 820 - 828. [Abstract] [Full Text] [PDF]

				L. Z. Benet There Are No Useful CYP3A Probes that Quantitatively Predict the In Vivo Kinetics of Other CYP3A Substrates and No Expectation that One Will Be Found Mol. Interv., April 1, 2005; 5(2): 79 - 83. [Abstract] [Full Text] [PDF]

				L. Liu and K. S. Pang THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING Drug Metab. Dispos., January 1, 2005; 33(1): 1 - 9. [Abstract] [Full Text] [PDF]

				E. D. Kharasch, A. Walker, C. Hoffer, and P. Sheffels Evaluation of First-Pass Cytochrome P4503A (CYP3A) and P-Glycoprotein Activities Using Alfentanil and Fexofenadine in Combination J. Clin. Pharmacol., January 1, 2005; 45(1): 79 - 88. [Abstract] [Full Text] [PDF]

				J. L. Lam and L. Z. Benet HEPATIC MICROSOME STUDIES ARE INSUFFICIENT TO CHARACTERIZE IN VIVO HEPATIC METABOLIC CLEARANCE AND METABOLIC DRUG-DRUG INTERACTIONS: STUDIES OF DIGOXIN METABOLISM IN PRIMARY RAT HEPATOCYTES VERSUS MICROSOMES Drug Metab. Dispos., November 1, 2004; 32(11): 1311 - 1316. [Abstract] [Full Text] [PDF]

				H. Sun, Y. Huang, L. Frassetto, and L. Z. Benet EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN Drug Metab. Dispos., November 1, 2004; 32(11): 1239 - 1246. [Abstract] [Full Text] [PDF]